Recipharm and CTC Enter Collaboration

News
Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and ManagementPTSM: Pharmaceutical Technology Sourcing and Management-07-02-2014
Volume 10
Issue 7

Recipharm and CTC will offer packages for Phase I studies.

Clinical Trial Consultants AB (CTC), a specialist CRO focused on early clinical studies in translational medicine, and Recipharm Pharmaceutical Development AB, a Sweden-based CDMO, have entered into a collaboration. Together the two companies will offer a complete set of packages for Phase I studies including development and manufacture of clinical trial material. The packages will cover planning, performing, and evaluation of the clinical trial.

Source: Clinical Trial Consultants AB

Articles in this issue
GSK Offers $1 Million Award for Healthcare Innovations
Covance MarketPlace Connects Biotech with Potential Partners
Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts
Changing Market Dynamics Require New Approaches to Innovation
use_FIgure-1-847622-1408516350395.jpg
Cost Is No Longer the Driving Force for Outsourcing
Cytovance Biologics Manufactures AM0010 for ARMO BioSciences
Wechsler_Jill-847623-1408516347347.jpg
Globalization Challenges Drug Regulators
Aesica Pharmaceuticals S.r.I. Implements Serialization System
Frontage Labs Plans Expansion of CMC Facility
Novartis Hosts 13th Annual Malaria Expert Panel
Rentschler Invests in New Stainless-Steel Bioreactors
Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug
Recipharm and CTC Enter Collaboration
More than 430 New Medicines in Development for Chronic Diseases
SGS Introduces the Cobas 6000 Analyzer Series
Recent Videos
Related Content
Nano particle molecule. Nano medicine and nanotechnology biotechnology concept. Organic or inorganic polymeric sphere, capsule, quantum. | Image Credit: ©Irina - stock.adobe.com

Enhancing Solubility and Bioavailability with Nanotechnology

Cynthia A. Challener
April 7th 2025
Article

Advanced solutions are improving drug dissolution, absorption, and overall therapeutic performance.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Macro view on vials | Image Credit: © yuriygolub - stock.adobe.com

Extractable and Leachable Challenges in Lyophilized Drug Products

Alan Xu;Piet Christiaens
April 5th 2025
Article

The authors examine the risks of extractables and leachables, and present solutions that emphasize the importance of a strategic, multi-prong approach.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

The show floor at INTERPHEX 2025. | Image Credit: © Patrick Lavery/PharmTech Group

Recapping INTERPHEX 2025: Pharma Looks Toward the Future

Patrick Lavery
April 4th 2025
Article

The yearly convention in New York City showcased new and emerging technologies and gave participating exhibitors a chance to unveil their strategies for the second half of the 2020s.

Nitrosamine Impurities inscription on wooden chips with stethoscopes on white background. Nitrosamine Impurities in certain drugs and pharmaceutical products concept. | Image credit: ©Debalina - stock.adobe.com

N-Nitrosamine Impurities and FDA’s Recommendations for Acceptable Intake Limits

Susan Haigney
April 4th 2025
Article

Josh Hoerner, general manager of Purisys, provides his perspective on FDA’s recommendations for acceptable intake limits for N-nitrosamine impurities.